Replicon-based screening for inhibitors of alphaviruses

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$958,581.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI062185-01
Award Id:
71272
Agency Tracking Number:
AI062185
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
893 N. WARSON RD., ST. LOUIS, MO, 63141
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
PAUL OLIVO
(314) 812-8157
olivo@apath.com
Business Contact:
L MILTON
(314) 812-8160
MILTON@APATH.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): The goal in this study is to develop a cell-based assay to screen compounds for antiviral activity against certain members of the Togavirus family. We are particularly targeting the more pathogenic encephalitis-causing viruses from the alphavirus genus, such as Venezuelan equine encephalitis virus (VEEV), Eastern equine encephalitis virus (EEEV) and Western equine encephalitis virus (WEEV) which have been listed as category B bioterrorism agents. Sindbis virus and VEEV are prototypic alphaviruses that have been extensively used as vectors for expression of foreign genes. These agents provide us with useful systems to promote the development of an antiviral screening program based on alphavirus replicons. This screening program will focus on using Sindbis and VEE replicon systems for high-throughput screening of small molecules. Using an Old World virus (Sindbis) and a New World virus (VEEV) in screening provides us with an opportunity to find broad-spectrum anti-alphavirus compounds in order to better deal with species, quasispecies and unknown alphavirus pathogens. We propose the following specific aims: 1) generate cells that transiently or constitutively express a reporter gene from a VEE replicon; 2) validate the replicon cells for screening; 3) screen synthetic and natural compound libraries using both our existing Sindbis replicons and newly made VEE replicons; 4) confirm the anti-viral activity of the most potent compounds. These efforts will contribute to the goal of finding therapeutic modalities to control these important pathogens.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government